Prophylactic Ivermectin in COVID-19 Contacts

Z

Zagazig University

Status and phase

Completed
Phase 3
Phase 2

Conditions

COVID

Treatments

Drug: Ivermectin Tablets

Study type

Interventional

Funder types

Other

Identifiers

NCT04422561
ZU-IRB#6150/31-5-2020

Details and patient eligibility

About

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19

Enrollment

340 patients

Sex

All

Ages

16 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

family contact of confirmed COVID-19 case

Exclusion criteria

  • refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

340 participants in 2 patient groups

Ivermectin group
Experimental group
Description:
Contacts who will receive prophylactic ivermectin
Treatment:
Drug: Ivermectin Tablets
Control group
No Intervention group
Description:
Contacts who will be only observed without prophylaxis

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems